Xilio Therapeutics, Inc. - 10-Q Filing
Xilio Therapeutics reports Q3 2026 financial results featuring ongoing collaboration with AbbVie and Gilead Sciences.
Tickers: $XLO
Xilio Therapeutics reports Q3 2026 financial results featuring ongoing collaboration with AbbVie and Gilead Sciences.
Tickers: $XLO